BMC128 was developed by Biomica, Evogene’s subsidiary, and is currently completing Phase 1 clinical study, showing promising early clinical results   Rehovot, Israel and Shanghai, China – February 4, 2026 – Evogene Ltd. (Nasdaq/TASE: EVGN) ("Evogene"), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, and Shanghai Lishan Biotech Co., Ltd. ("Lishan Biotech"), a China-based clinical-stage biotechnology company focused on innovative therapies in the fields of immunity and inflammation, today announced that Biomica Ltd. ("Biomica"), Evogene’s subsidiary and Lishan Biotech entered into an exclusive worldwide licensing agreement for BMC128 (designated as LS-LBP-002 by Lishan Biotech), a first-in-class microbiom...

In order to highlight the innovation and vitality of Zhangjiang's life science industry, the WeChat official account of "Zhangjiang Pharmaceutical Valley" launched the column of "New Talents of Pharmaceutical Valley", and invited new enterprises of Zhangjiang Pharmaceutical Valley to have in-depth dialogue and decode innovation. In this issue, we will have a conversation with Dr. William Chen, Chairman of Shanghai Lishan Biopharmaceutical Co., Ltd. (hereinafter referred to as "Lishan Biotech"), to learn how the company has embarked on a path of cross-border integration and innovation. William Chen, Chairman of Lishan Biotechnology   At the National Finals of the 3rd National Postdoctoral Innovation and Entrepreneurship Competition, which concluded in October 2025, Dr.William Chen, Chairman of Lishan Biotech, led the "Inte...

The final of the 3rd National Postdoctoral Innovation and Entrepreneurship Competition, co hosted by the Ministry of Human Resources and Social Security and the People's Government of Fujian Province, was successfully concluded in Quanzhou, Fujian Province from October 26-28, 2025. After fierce competition and rigorous evaluation, Dr. William Chen, Chairman of Lishan Biotechnology, led the project of "Intestinal Microbial Live Biopharmaceuticals for Crohn's Disease Treatment", which stood out among many excellent participating projects in the biopharmaceutical field and won the silver medal in this competition. This innovation competition has received high attention, with more projects and participants than the first and second editions. It gathers seven major tracks including new generation information technology and artificial intelligence, high-end e...

On October 16, 2025, Shanghai Lishan Biopharmaceutical Co., Ltd. officially obtained the GB/T 19001-2016/ISO 9001:2015 quality management system certification issued by the international authoritative certification body BCC.     The Road to Building the ISO9001 Quality Management System in Lishan Biotech ISO9001 is the globally recognized and most mature quality management system framework, published by the International Organization for Standardization (ISO) and widely adopted by various organizations around the world. This system is based on "quality" and rooted in "quality", committed to continuously improving product and service levels through systematic and standardized management. Obtaining ISO9001 certification is not only a powerful manifestation of a company's pursuit of excellence, but also an important cornerstone for achievin...